Ivosidenib for advanced IDH1-mutant cholangiocarcinoma

被引：0
|
作者：
Gervaso, Lorenzo [1 ]
Pellicori, Stefania [1 ]
Fazio, Nicola [1 ]
机构：
[1] European Inst Oncol, Div Gastrointestinal Med Oncol & Neuroendocrine T, I-20141 Milan, Italy
来源：
LANCET ONCOLOGY | 2020年 / 21卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E370 / E370
页数：1
相关论文
共 50 条
  • [11] Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review
    Sumbly, Vikram
    Landry, Ian
    Rizzo, Vincent
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (01)
  • [12] Population Pharmacokinetics of Ivosidenib (AG-120) in Patients with IDH1-Mutant Advanced Hematologic Malignancies
    Le, Kha
    Wada, Russ
    Dai, David
    Fan, Bin
    Liu, Guowen
    Liu, Hua
    Attar, Eyal C.
    Agresta, Samuel V.
    Yang, Hua
    BLOOD, 2018, 132
  • [13] Tibsovo® (ivosidenib) - first targeted Therapy for IDH1-mutant Tumor Diseases
    Sonnet, Miriam
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (09)
  • [14] Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies
    Jiang, Xuemin
    Wada, Russ
    Poland, Bill
    Kleijn, Huub Jan
    Fan, Bin
    Liu, Guowen
    Liu, Hua
    Kapsalis, Stephanie
    Yang, Hua
    Le, Kha
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (03): : 942 - 953
  • [15] INCREASED SUSCEPTIBILITY TO BET INHIBITION IN IDH1-MUTANT INTRAHEPATIC CHOLANGIOCARCINOMA
    Fujiwara, Hiroaki
    Tateishi, Keisuke
    Kato, Hiroyuki
    Nakatsuka, Takuma
    Tanaka, Yasuo
    Ijichi, Hideaki
    Koike, Kazuhiko
    GASTROENTEROLOGY, 2019, 156 (06) : S771 - S771
  • [16] Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced solid tumors from a phase 1 study.
    Fan, Bin
    Mellinghoff, Ingo K.
    Wen, Patrick Y.
    Pandya, Shuchi Sumant
    Jiang, Liewen
    Liu, Guowen
    Nimkar, Tara
    Yang, Hua
    Dai, David
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [17] IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
    Khurshed, Mohammed
    Aarnoudse, Niels
    Hulsbos, Renske
    Hira, Vashendriya V. V.
    van Laarhoven, Hanneke W. M.
    Wilmink, Johanna W.
    Molenaar, Remco J.
    van Noorden, Cornelis J.
    FASEB JOURNAL, 2019, 33
  • [18] IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
    Khurshed, Mohammed
    Aarnoudse, Niels
    Hulsbos, Renske
    Hira, Vashendriya V. V.
    van Laarhoven, Hanneke W. M.
    Wilmink, Johanna W.
    Molenaar, Remco J.
    van Noorden, Cornelis J. F.
    FASEB JOURNAL, 2018, 32 (11): : 6344 - 6352
  • [19] Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
    Choe, Sung
    Wang, Hongfang
    DiNardo, Courtney D.
    Stein, Eytan M.
    de Botton, Stephane
    Roboz, Gail J.
    Altman, Jessica K.
    Mims, Alice S.
    Watts, Justin M.
    Pollyea, Daniel A.
    Fathi, Amir T.
    Tallman, Martin S.
    Kantarjian, Hagop M.
    Stone, Richard M.
    Quek, Lynn
    Konteatis, Zenon
    Dang, Lenny
    Nicolay, Brandon
    Nejad, Parham
    Liu, Guowen
    Zhang, Vickie
    Liu, Hua
    Goldwasser, Meredith
    Liu, Wei
    Marks, Kevin
    Bowden, Chris
    Biller, Scott A.
    Attar, Eyal C.
    Wu, Bin
    BLOOD ADVANCES, 2020, 4 (09) : 1894 - 1905
  • [20] Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
    Ingo K. Mellinghoff
    Min Lu
    Patrick Y. Wen
    Jennie W. Taylor
    Elizabeth A. Maher
    Isabel Arrillaga-Romany
    Katherine B. Peters
    Benjamin M. Ellingson
    Marc K. Rosenblum
    Saewon Chun
    Kha Le
    Ania Tassinari
    Sung Choe
    Youssef Toubouti
    Steven Schoenfeld
    Shuchi S. Pandya
    Islam Hassan
    Lori Steelman
    Jennifer L. Clarke
    Timothy F. Cloughesy
    Nature Medicine, 2023, 29 : 615 - 622
12345